MDXG vs. XENT, ATEC, CRY, OFIX, SIBN, HAE, PRCT, AXNX, TNDM, and NARI
Should you be buying MiMedx Group stock or one of its competitors? The main competitors of MiMedx Group include Intersect ENT (XENT), Alphatec (ATEC), CryoLife (CRY), Orthofix Medical (OFIX), SI-BONE (SIBN), Haemonetics (HAE), PROCEPT BioRobotics (PRCT), Axonics (AXNX), Tandem Diabetes Care (TNDM), and Inari Medical (NARI). These companies are all part of the "medical" sector.
MiMedx Group (NASDAQ:MDXG) and Intersect ENT (NASDAQ:XENT) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, analyst recommendations, community ranking, valuation, dividends, risk and institutional ownership.
79.2% of MiMedx Group shares are held by institutional investors. Comparatively, 92.5% of Intersect ENT shares are held by institutional investors. 1.3% of MiMedx Group shares are held by company insiders. Comparatively, 2.1% of Intersect ENT shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
MiMedx Group has a net margin of 18.63% compared to Intersect ENT's net margin of -161.94%. MiMedx Group's return on equity of 39.42% beat Intersect ENT's return on equity.
Intersect ENT received 372 more outperform votes than MiMedx Group when rated by MarketBeat users. However, 77.27% of users gave MiMedx Group an outperform vote while only 60.33% of users gave Intersect ENT an outperform vote.
MiMedx Group has a beta of 1.44, suggesting that its stock price is 44% more volatile than the S&P 500. Comparatively, Intersect ENT has a beta of 1.45, suggesting that its stock price is 45% more volatile than the S&P 500.
In the previous week, MiMedx Group had 3 more articles in the media than Intersect ENT. MarketBeat recorded 3 mentions for MiMedx Group and 0 mentions for Intersect ENT. MiMedx Group's average media sentiment score of 1.12 beat Intersect ENT's score of 0.00 indicating that MiMedx Group is being referred to more favorably in the media.
MiMedx Group has higher revenue and earnings than Intersect ENT. Intersect ENT is trading at a lower price-to-earnings ratio than MiMedx Group, indicating that it is currently the more affordable of the two stocks.
MiMedx Group presently has a consensus target price of $12.25, indicating a potential upside of 60.13%. Given MiMedx Group's higher probable upside, research analysts clearly believe MiMedx Group is more favorable than Intersect ENT.
Summary
MiMedx Group beats Intersect ENT on 12 of the 17 factors compared between the two stocks.
Get MiMedx Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for MDXG and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MDXG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
MiMedx Group Competitors List
Related Companies and Tools
